“Biosimilars”

14 result(s)
Specialty
The Impact of Autoimmune Conditions on Women
Women are overrepresented among autoimmune patients so may benefit the most from new biosimilar treatments More
Briefing
Specialty
Member Education: How We Help Build Awareness
Supporting members through prescription changes with CVS Health’s many touchpoints, expertise, and data More
Briefing
Drug Pipeline
Biosimilars in the Autoimmune Category
Biosimilars in the Autoimmune Category More
Briefing
Specialty
The First Biosimilar to Humira Is Here. Now What?
The First Biosimilar to Humira Is Here More
Briefing
Drug Pipeline
Keeping an Eye on the Drug Pipeline
New Drugs for Ophthalmic Disorders on the Horizon More
Briefing
Drug Pipeline
Expanding Therapies, Indications and Implications for Payors
2022 Marketplace Outlook: Expanding Therapies, Indications and Implications for Payors More
Briefing
Cost Management
Assessing New-to-Market Biologics and Biosimilars
CVS Health offers strategies for addressing new-to-market products to ensure access to clinically appropriate insulin or other medications. More
Commentary
Drug Pipeline
Biosimilars Help Support Members, Payors with Affordable Options
Biosimilars help to increase market competition. Balancing the use of biosimilars and biologics with strategic formulary decisions deliver lower costs. More
Briefing
Drug Pipeline
Helping Contain Brand Biologic Costs with Formulary Changes
Biosimilars are a critical tool PBMs can use to help increase market competition and lower costs – we made changes to our template formularies for categories that now have... More
Feature
Person On Laptop
Specialty
Today's Specialty Landscape
Specialty spend continues to grow rapidly; CVS Health continues to innovate with strategies that reduced the trend impact of inflation significantly, to 1.7 percent. More
Video